UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (3962) 3962
life sciences & biomedicine (3889) 3889
humans (3813) 3813
male (3351) 3351
hypolipidemic agents - therapeutic use (2652) 2652
animals (2306) 2306
hypolipidemic agents - administration & dosage (1962) 1962
female (1944) 1944
hypolipidemic agents - pharmacology (1787) 1787
middle aged (1500) 1500
pharmacology & pharmacy (1293) 1293
rats (1253) 1253
adult (1061) 1061
aged (1027) 1027
triglycerides - blood (952) 952
hyperlipidemias - drug therapy (942) 942
risk factors (871) 871
lipids - blood (824) 824
cholesterol - blood (774) 774
cholesterol (749) 749
lipids (736) 736
cardiovascular system & cardiology (699) 699
hypolipidemic agents - adverse effects (674) 674
treatment outcome (653) 653
abridged index medicus (624) 624
cholesterol, ldl - blood (592) 592
cardiac & cardiovascular systems (557) 557
drug therapy, combination (550) 550
mice (517) 517
rats, wistar (515) 515
liver - drug effects (507) 507
liver - metabolism (488) 488
cholesterol, hdl - blood (486) 486
diabetes (481) 481
dyslipidemias - drug therapy (465) 465
dose-response relationship, drug (458) 458
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (458) 458
statins (455) 455
general & internal medicine (446) 446
cardiovascular diseases - prevention & control (435) 435
medicine, general & internal (435) 435
cardiovascular disease (422) 422
triglycerides (415) 415
research (404) 404
atherosclerosis (390) 390
rats, sprague-dawley (386) 386
drug therapy (385) 385
endocrinology & metabolism (383) 383
hyperlipidemias - blood (381) 381
time factors (377) 377
administration, oral (363) 363
care and treatment (362) 362
hyperlipidemia (362) 362
health aspects (352) 352
plant extracts - pharmacology (335) 335
analysis (326) 326
hypercholesterolemia - drug therapy (324) 324
fenofibrate (322) 322
hypolipidemic agents - chemistry (318) 318
nutrition & dietetics (318) 318
chemistry, medicinal (316) 316
double-blind method (315) 315
biochemistry & molecular biology (314) 314
hypoglycemic agents - therapeutic use (308) 308
diet (302) 302
fenofibrate - therapeutic use (300) 300
fenofibrate - administration & dosage (293) 293
hypoglycemic agents - pharmacology (293) 293
blood glucose - metabolism (289) 289
low density lipoproteins (282) 282
hypolipidemic agents - pharmacokinetics (279) 279
lipid metabolism (272) 272
diabetes mellitus, type 2 - drug therapy (271) 271
chemistry (270) 270
disease models, animal (268) 268
insulin resistance (268) 268
medicine & public health (266) 266
peripheral vascular disease (264) 264
cardiovascular diseases (258) 258
lipoproteins (255) 255
clinical trials as topic (252) 252
phytotherapy (252) 252
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (251) 251
lipid metabolism - drug effects (244) 244
cardiology (240) 240
physical sciences (240) 240
cardiovascular (236) 236
anticholesteremic agents (233) 233
dosage and administration (231) 231
diabetes mellitus, experimental - drug therapy (228) 228
physiological aspects (228) 228
rodents (228) 228
simvastatin (227) 227
niacin - administration & dosage (226) 226
niacin - therapeutic use (225) 225
biomarkers - blood (224) 224
hypercholesterolemia (223) 223
hyperlipidemias - complications (221) 221
internal medicine (215) 215
fenofibrate - pharmacology (214) 214
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5278) 5278
German (110) 110
Russian (100) 100
Japanese (85) 85
Spanish (56) 56
French (47) 47
Chinese (42) 42
Italian (23) 23
Swedish (20) 20
Hungarian (18) 18
Danish (17) 17
Norwegian (17) 17
Portuguese (16) 16
Polish (15) 15
Czech (14) 14
Ukrainian (6) 6
Lithuanian (3) 3
Slovak (3) 3
Bulgarian (1) 1
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Food & function, ISSN 2042-6496, 12/2014, Volume 6, Issue 1, pp. 296 - 33
Beneficial effects of green tea ( Camellia sinensis , Theaceae) extracts against obesity have been reported; however, the anti-obesity ability of the major... 
Food Science & Technology | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Science & Technology | Camellia sinensis - chemistry | Liver - pathology | Adipose Tissue, White - immunology | Obesity - immunology | Male | Obesity - blood | Anti-Obesity Agents - therapeutic use | Dietary Supplements - analysis | Liver - immunology | Polysaccharides - administration & dosage | Hypolipidemic Agents - chemistry | Polysaccharides - therapeutic use | Hypolipidemic Agents - analysis | Anti-Obesity Agents - administration & dosage | Specific Pathogen-Free Organisms | Anti-Inflammatory Agents, Non-Steroidal - analysis | Plant Extracts - isolation & purification | Random Allocation | Hyperlipidemias - prevention & control | Rats, Sprague-Dawley | Obesity - pathology | Anti-Obesity Agents - chemistry | Obesity - prevention & control | Polyphenols - analysis | Hypolipidemic Agents - therapeutic use | Polyphenols - therapeutic use | Plant Extracts - therapeutic use | Leptin - antagonists & inhibitors | Plant Extracts - chemistry | Caffeine - analysis | Caffeine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Anti-Obesity Agents - analysis | Plant Extracts - administration & dosage | Leptin - blood | Caffeine - therapeutic use | Polysaccharides - isolation & purification | Food Handling | Cytokines - blood | Plant Leaves - chemistry | Adipose Tissue, White - pathology | Polyphenols - isolation & purification | Polysaccharides - analysis | Caffeine - isolation & purification | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Hyperlipidemias - etiology | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Hypolipidemic Agents - administration & dosage | Cytokines - antagonists & inhibitors | Polyphenols - administration & dosage | Index Medicus
Journal Article
Food & function, ISSN 2042-6496, 3/2015, Volume 6, Issue 3, pp. 92 - 99
...)-induced diabetic BALB/c mice. It was observed that fasting blood glucose (FBG) levels in both models were reduced after a 4-week oral administration of ASP or metformin, and abnormal fasting serum insulin (FINS... 
Food Science & Technology | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Science & Technology | Angelica sinensis - chemistry | Prediabetic State - metabolism | Liver - pathology | Prediabetic State - diet therapy | Adipose Tissue, White - immunology | Adipose Tissue, White - metabolism | Diabetes Mellitus, Type 2 - diet therapy | Male | Muscle, Skeletal - metabolism | Anti-Inflammatory Agents, Non-Steroidal - isolation & purification | Diabetes Mellitus, Type 2 - metabolism | Liver - immunology | Glycogen - metabolism | Muscle, Skeletal - immunology | Hypoglycemic Agents - administration & dosage | Polysaccharides - isolation & purification | Diabetes Mellitus, Type 2 - immunology | Prediabetic State - immunology | Polysaccharides - administration & dosage | Prediabetic State - pathology | Glycogen - agonists | Hypoglycemic Agents - therapeutic use | Lipid Metabolism Disorders - prevention & control | Polysaccharides - therapeutic use | Adipose Tissue, White - pathology | Hyperglycemia - prevention & control | Hyperinsulinism - prevention & control | Liver - metabolism | Hypolipidemic Agents - isolation & purification | Insulin Resistance | Pancreas - pathology | Pancreas - metabolism | Random Allocation | Pancreas - immunology | Hyperlipidemias - prevention & control | Hypoglycemic Agents - isolation & purification | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Plant Roots - chemistry | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Hypolipidemic Agents - administration & dosage | Hypolipidemic Agents - therapeutic use | Mice, Inbred BALB C | Diabetes Mellitus, Type 2 - pathology | Index Medicus
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 12/2009, Volume 37, Issue 12, pp. 2359 - 2366
Gemfibrozil 1- O -β-glucuronide is a mechanism-based inhibitor of cytochrome P450 2C8. We studied the recovery of CYP2C8 activity after discontinuation of... 
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Cytochrome P-450 CYP2C8 | Area Under Curve | Enzyme Inhibitors - blood | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Half-Life | Male | Carbamates - administration & dosage | Carbamates - pharmacokinetics | Organic Anion Transporters - metabolism | Piperidines - blood | Enzyme Inhibitors - administration & dosage | Young Adult | Hypoglycemic Agents - blood | Hypolipidemic Agents - blood | Organic Anion Transporters - genetics | Drug Interactions | Molecular Probes - pharmacokinetics | Enzyme Inhibitors - pharmacokinetics | Hypoglycemic Agents - administration & dosage | Biotransformation | Molecular Probes - administration & dosage | Female | Piperidines - pharmacokinetics | Gemfibrozil - administration & dosage | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Hypoglycemic Agents - pharmacokinetics | Piperidines - administration & dosage | Administration, Oral | Gemfibrozil - blood | Molecular Probes - blood | Glucuronates - blood | Carbamates - blood | Gemfibrozil - pharmacokinetics | Genotype | Aryl Hydrocarbon Hydroxylases - metabolism | Glucuronates - pharmacokinetics | Blood Glucose - drug effects | Cross-Over Studies | Phenotype | Models, Biological | Hypolipidemic Agents - administration & dosage | Gemfibrozil - analogs & derivatives | Hypolipidemic Agents - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Index Medicus
Journal Article
European journal of nutrition, ISSN 1436-6215, 10/2013, Volume 53, Issue 3, pp. 973 - 980
Cumulative evidence suggests that moderate red wine consumption protects the cardiovascular system. The effect of cultured cells derived from red grape berry... 
Chemistry | Nutrition | Endothelin-1 | Rats | Blood pressure | Endothelial NO synthase | Metabolic syndrome | Red grape-cultured cell | Life Sciences & Biomedicine | Nutrition & Dietetics | Science & Technology | Fruit - cytology | Vitis - chemistry | Human Umbilical Vein Endothelial Cells - metabolism | Hypolipidemic Agents - metabolism | Vasodilator Agents - therapeutic use | Humans | Antihypertensive Agents - administration & dosage | Male | Antihypertensive Agents - metabolism | Hypertension - etiology | Pigments, Biological - metabolism | Plant Extracts - administration & dosage | Plant Extracts - metabolism | Hyperinsulinism - etiology | Vasodilator Agents - metabolism | Metabolic Syndrome - physiopathology | Hypertension - prevention & control | Metabolic Syndrome - diet therapy | Nitric Oxide Synthase Type III - metabolism | Fruit - metabolism | Hyperinsulinism - prevention & control | Endothelin-1 - metabolism | Fruit - chemistry | Cells, Cultured | Antihypertensive Agents - therapeutic use | Rats, Sprague-Dawley | Vitis - cytology | Hypertriglyceridemia - prevention & control | Animals | Human Umbilical Vein Endothelial Cells - enzymology | Hypertriglyceridemia - etiology | Hypolipidemic Agents - administration & dosage | Hypolipidemic Agents - therapeutic use | Vitis - metabolism | Dietary Supplements | Plant Extracts - therapeutic use | Vasodilator Agents - administration & dosage | Hypertension | Nitric oxide | Resveratrol | Polyphenols | Triglycerides | Fructose | Index Medicus
Journal Article
Diabetes, obesity & metabolism, ISSN 1463-1326, 07/2017, Volume 19, Issue 12, pp. 1762 - 1772
...INTRODUCTION Pharmacological administration of fibroblast growth factor 21 (FGF21) improves insulin sensitivity, corrects dyslipidaemia and decreases body... 
fibroblast growth factor 21 | IGF‐1 | blood pressure | heart rate | type 2 diabetes | bone biomarkers | IGF-1 | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypertriglyceridemia - drug therapy | Fibroblast Growth Factors - adverse effects | Follow-Up Studies | Obesity - drug therapy | Species Specificity | Humans | Middle Aged | Half-Life | Anti-Obesity Agents - adverse effects | Male | Obesity - blood | Anti-Obesity Agents - therapeutic use | Bone Remodeling - drug effects | Delayed-Action Preparations - administration & dosage | Dose-Response Relationship, Drug | Anti-Obesity Agents - pharmacokinetics | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Fibroblast Growth Factors - administration & dosage | Hypertension - chemically induced | Delayed-Action Preparations - pharmacokinetics | Female | Drug Resistance | Fibroblast Growth Factors - therapeutic use | Body Mass Index | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Hypolipidemic Agents - adverse effects | Anti-Obesity Agents - administration & dosage | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Drug Administration Schedule | Obesity - complications | Biomarkers - blood | Hypertension - physiopathology | Hypertriglyceridemia - blood | Animals | Fibroblast Growth Factors - pharmacokinetics | Delayed-Action Preparations - adverse effects | Hypertriglyceridemia - complications | Hypolipidemic Agents - administration & dosage | Delayed-Action Preparations - therapeutic use | Hypolipidemic Agents - therapeutic use | Infusions, Intravenous | Hypolipidemic Agents - pharmacokinetics | Type 2 diabetes | Obesity | Heart beat | Blood cholesterol | Collagen | Analysis | Body weight | Primates | Fibroblast growth factors | Blood pressure | Fibroblast growth factor | Pharmacodynamics | Diabetes mellitus | Homeostasis | Lipids | Triglycerides | Body weight loss | Bone turnover | Monkeys & apes | Cholesterol | Adiponectin | Heart rate | Rodents | Fibroblasts | Atorvastatin | Lead | Safety | Pharmacokinetics | Growth factors | Diabetes mellitus (non-insulin dependent) | Lipoproteins (high density) | Index Medicus
Journal Article
American Journal of Cardiovascular Drugs, ISSN 1175-3277, 04/2010, Volume 10, Issue 2, pp. 95 - 103
Background The Polycap™ (polypill; aspirin [acetylsalicylic acid], ramipril, simvastatin, atenolol, and hydrochlorothiazide) was found to be safe and effective... 
Drug-interactions | Ramipril, pharmacokinetics | Aspirin, pharmacokinetics | Hydrochlorothiazide, pharmacokinetics | Hydrochlorothiazide/atenolol/ramipril/simvastatin/aspirin, pharmacokinetics | Salicylic-acid, pharmacokinetics | Atenolol, pharmacokinetics | Risk-factors | Hydrochlorothiazide/atenolol/ramipril/simvastatin/aspirin, drug interactions | Simvastatin, pharmacokinetics | Cardiovascular-disorders, treatment | Pharmacotherapy | Medicine & Public Health | Cardiology | Pharmacology/Toxicology | Cardiac & Cardiovascular Systems | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Hydrochlorothiazide - pharmacokinetics | Simvastatin - adverse effects | Area Under Curve | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Aspirin - pharmacokinetics | Biological Availability | Male | Aspirin - administration & dosage | Ramipril - administration & dosage | Young Adult | Capsules | Drug Interactions | Aspirin - adverse effects | Atenolol - pharmacokinetics | Platelet Aggregation Inhibitors - administration & dosage | Adult | Platelet Aggregation Inhibitors - pharmacokinetics | Atenolol - administration & dosage | Ramipril - adverse effects | Tandem Mass Spectrometry - methods | Platelet Aggregation Inhibitors - adverse effects | Hydrochlorothiazide - adverse effects | Cardiovascular Diseases - etiology | Hypolipidemic Agents - adverse effects | Administration, Oral | Simvastatin - administration & dosage | Risk Factors | Ramipril - pharmacokinetics | Hydrochlorothiazide - administration & dosage | Antihypertensive Agents - pharmacokinetics | Simvastatin - pharmacokinetics | Antihypertensive Agents - adverse effects | Cross-Over Studies | Adolescent | Hypolipidemic Agents - administration & dosage | Atenolol - adverse effects | Chromatography, Liquid - methods | Hypolipidemic Agents - pharmacokinetics | Drug Combinations | Prevention | Complications and side effects | Drug interactions | Dosage and administration | Research | Cardiovascular diseases | Risk factors | Cardiovascular agents | Index Medicus
Journal Article
Journal Article